Govt moves to make three key cancer drugs cheaper
- Aurangabad arms haul case: MCOCA court convicts 12 including Abu Jundal
- Rajnath Singh to visit Pakistan in August, attend Saarc meet
- Indigo flight makes emergency landing in Mumbai after passenger creates ruckus
- Assam floods: Sonowal directs ministers to visit constituencies as situation worsens
- Bhagwant Mann: Didn't breach security, even TV channels broadcast from Parliament
In a move that will benefit thousands of cancer patients but is likely to upset pharma MNCs, the Department of Pharmaceuticals has started the process of issuing compulsory licences for three commonly used anti-cancer drugs, Trastuzumab (or Herceptin, used for breast cancer), Ixabepilone (used for chemotherapy) and Dasatinib (used to treat leukaemia).
Compulsory licensing (CL) by the government allows a domestic company to manufacture and sell a generic version of a patented drug with or without the consent of the patent-holder. Sections 84 and 92 of the Indian Patents Act, 1970, provide for CL in cases where the patented drug is unavailable, unaffordable, or if there are problems with its supply in India. CL reduces the price of a drug manifold, and is a practice in many developing countries.
The first drug to be issued a compulsory licence in India was Bayer's Nexavar (sorafenib tosylate), a drug for liver cancer, last August. After the CL, Nexavar is available for Rs 8,880 per pack of 120 tablets (a month's dose), over 95% cheaper than its pre-CL price.
Trastuzumab, Ixabepilone and Dasatinib are all more expensive that Nexavar, costing Rs 50,000, Rs 70,000-80,000 and Rs 15,000 respectively for a month's dose.
- The amended act legalises child labour while claiming to do the opposite
- The concept of private members’ bill is central to a deliberative democracy
- Mahasweta Devi drew imaginary landscapes to narrate stories of the oppressed
- With the latest figures on industrial output, the case for a stimulus is pressing
- An open letter to new students entering Jawaharlal Nehru University
- Irom Sharmila calling off her fast against the AFSPA reflects the state’s failure to engage